-+ 0.00%
-+ 0.00%
-+ 0.00%
Seres Therapeutics Announces Three Presentations To Take Place At The 2026 European Society Of Clinical Microbiology And Infectious Diseases Global Congress, April 17-21
Share
Listen to the news

Presentations Details

Poster Presentation (Abstract 1726)

Title: Effect of investigational, live biotherapeutic, SER-155, on gastrointestinal (GI) microbiome composition in adults receiving allogeneic haematopoietic stem cell transplant (allo-HCT) in a randomised, placebo-controlled phase 1b trial

Session: PS073 – 10c: Infections related to haematopoietic stem cell transplantation

Date and Time: Sunday, February 19 at 12:00 CEST

Presenter: Dr. Elizabeth Halvorsen, Senior Director, Translational Biology at Seres Therapeutics

Oral Presentation (Abstract 8914)

Title: Recapturing individual inflammatory responses in IBD microbiomes using an in vitro colonic model (MiGut)

Session: OS100: Microbiome-host interplay in intestinal disease and under selection pressure

Date and Time: Monday, April 20 at 14:45 CEST

Presenter: Dr. Ines Moura, Lecturer in Medical Microbiology at the University of Leeds

Symposium Presentation

Title: Targeting the gut microbiome: an emerging trend in haematopoietic stem cell transplantation

Session: 10. Immune compromise & transplant ID - The role of the microbiome in shaping clinical outcomes in immunocompromised patients

Date and Time: Tuesday, April 21 at 8:30 CEST

Presenter: Dr. Jonathan (Tsoni) Peled, Bone Marrow Transplant Specialist at MSKCC

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending